Invion Past Earnings Performance
Past criteria checks 0/6
Invion's earnings have been declining at an average annual rate of -14.1%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 2.9% per year.
Key information
-14.1%
Earnings growth rate
-9.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 2.9% |
| Return on equity | -39.0% |
| Net Margin | -152.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now
Nov 22
We Think Invion (ASX:IVX) Can Afford To Drive Business Growth
Jul 07Here's Why We're Not Too Worried About Invion's (ASX:IVX) Cash Burn Situation
Mar 24Is Invion (ASX:IVX) In A Good Position To Invest In Growth?
Dec 08We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate
Aug 16A Look At The Fair Value Of Invion Limited (ASX:IVX)
Nov 04Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)
Mar 23We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth
Nov 26
Revenue & Expenses Breakdown
How Invion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -6 | 6 | 0 |
| 31 Mar 24 | 4 | -4 | 4 | 0 |
| 31 Dec 23 | 4 | -1 | 2 | 0 |
| 30 Sep 23 | 4 | -2 | 2 | 0 |
| 30 Jun 23 | 4 | -2 | 2 | 0 |
| 31 Mar 23 | 4 | -2 | 2 | 0 |
| 31 Dec 22 | 4 | -2 | 2 | 0 |
| 30 Sep 22 | 4 | -2 | 3 | 0 |
| 30 Jun 22 | 3 | -2 | 3 | 0 |
| 31 Mar 22 | 3 | -2 | 3 | 0 |
| 31 Dec 21 | 2 | -2 | 2 | 0 |
| 30 Sep 21 | 2 | -2 | 2 | 0 |
| 30 Jun 21 | 2 | -1 | 2 | 0 |
| 31 Mar 21 | 3 | -1 | 2 | 0 |
| 31 Dec 20 | 3 | -1 | 2 | 0 |
| 30 Sep 20 | 3 | -1 | 2 | 0 |
| 30 Jun 20 | 3 | -1 | 3 | 0 |
| 31 Dec 19 | 5 | -2 | 4 | 0 |
| 30 Sep 19 | 4 | -2 | 4 | 0 |
| 30 Jun 19 | 4 | -3 | 4 | 0 |
| 31 Dec 18 | 2 | -1 | 2 | 0 |
| 30 Sep 18 | 1 | -1 | 2 | 0 |
| 30 Jun 18 | 1 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -6 | 1 | 0 |
| 31 Dec 17 | 0 | -6 | 1 | 0 |
| 30 Sep 17 | 0 | -4 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | 0 | 1 | 0 |
| 31 Dec 16 | 0 | 2 | 2 | 0 |
| 30 Sep 16 | 0 | -1 | 3 | 0 |
| 30 Jun 16 | 0 | -4 | 3 | 0 |
| 31 Mar 16 | 0 | -8 | 4 | 0 |
| 31 Dec 15 | 0 | -11 | 4 | 0 |
| 30 Sep 15 | 0 | -12 | 4 | 0 |
| 30 Jun 15 | 0 | -13 | 5 | 0 |
| 31 Mar 15 | 0 | -11 | 5 | 0 |
| 31 Dec 14 | 0 | -9 | 5 | 0 |
| 30 Sep 14 | 0 | -8 | 4 | 0 |
| 30 Jun 14 | 0 | -7 | 4 | 0 |
| 31 Mar 14 | 0 | -6 | 4 | 0 |
| 31 Dec 13 | 0 | -5 | 3 | 0 |
Quality Earnings: IVX is currently unprofitable.
Growing Profit Margin: IVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVX is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: IVX has a negative Return on Equity (-38.98%), as it is currently unprofitable.